The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

被引:0
|
作者
Kerb R. [1 ]
Aynacioglu A.S. [2 ,3 ]
Brockmöller J. [2 ]
Schlagenhaufer R. [1 ]
Bauer S. [2 ]
Szekeres T. [4 ]
Hamwi A. [4 ]
Fritzer-Szekeres M. [4 ]
Baumgartner C. [5 ]
Öngen H.Z. [6 ]
Güzelbey P. [6 ]
Roots I. [2 ]
Brinkmann U. [1 ]
机构
[1] Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried
[2] Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin
[3] Department of Pharmacology, Medical Faculty, Pamukkale University, Denizli
[4] Institute of Clinical Chemistry, AKH-Wien, University of Vienna, Vienna
[5] Institute of Neurology, AKHWien, University of Vienna, Vienna
[6] Department of Pharmacology, University of Gaziantep
关键词
Pharmacogenetlcs; Polymorphism; TDM;
D O I
10.1038/sj.tpj.6500025
中图分类号
学科分类号
摘要
Phenytoin, an anticonvulsant, exhibits nonlinear pharmacokinetics with large interindividual differences. Because of its small therapeutic range with the risk of therapeutic failure or adverse drug effects in susceptible persons, therapeutic drug monitoring is frequently applied. The interindividual differences in dose response can partially be explained by known genetic polymorphisms in the metabolic enzyme CYP2C9 but a large deal of individual variability remains still unexplained. Part of this variability might be accounted for by variable uptake of phenytoin, which is a substrate of p-glycoprotein, encoded by the human MDR1 gene. We evaluated, whether phenytoin plasma levels correlate with a polymorphism in the MDR1 gene, C3435T, which is associated with intestinal PCP activity. Genotyping and analyses of plasma levels of phenytoin and metabolites in 96 healthy Turkish volunteers showed that the MDR1C > T3435 polymorphism affects phenytoin plasma levels (P = 0.064) and the metabolic ratio of p-HPPH vs phenytoin (MDR1*TT genotype, P = 0.026). The MDR1*CC genotype is more common in volunteers with low phenytoin levels (P ≤ 0.001, χ2 test). A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR1*T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability. The regression equation that fitted the data best included the number of mutant CYP2C9 and MDR*T alleles as predictory variables and explained 15.4% of the variability of phenytoin data (r2 = 0.154, P = 0.0002). Furthermore, analysis of CYP2C9 and MDR1 genotypes in 35 phenytoin-treated patients recruited from therapeutic drug monitoring showed that combined CYP2C9 and MDR1 analysis has some predictive value not only in the controlled settings of a clinical trial, but also in the daily clinical practice. © 2001 Nature Publishing Group All rights reserved.
引用
收藏
页码:204 / 210
页数:6
相关论文
共 50 条
  • [31] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [32] Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
    Hirota, Takeshi
    Eguchi, Shunsuke
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (01) : 28 - 37
  • [33] Influence Of The Polymorphism In CYP2C9, CYP2C19 And MDR1 On Risk Of Development Of Side Effects Due To Valproic Acide In Patients With Epilepsy
    Sergeeva, T.
    Glotov, A.
    Danilova, M.
    Odintsova, G.
    Koroleva, N.
    EPILEPSIA, 2019, 60 : 174 - 174
  • [34] INFLUENCE OF CYP3A5, CYP2C19 AND MDR1 GENETIC POLYMORPHISMS ON THE PHARMACOKINETICS OF CILOSTAZOL
    Kim, Se-Mi
    Park, Sun-Ae
    Kang, Hyun-Ah
    Cho, Hea-Young
    Shin, Sae-Byeok
    Lee, Yong-Bok
    DRUG METABOLISM REVIEWS, 2008, 40 : 151 - 151
  • [35] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [36] Relevance of CYP2C9, CYP2C19, CYP2B6 and GSTA1 polymorphisms on cyclophosphamide kinetics
    Timm, R
    Kaiser, R
    Sezer, O
    Weisz, K
    Roots, I
    Cascorbi, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R149 - R149
  • [37] Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
    Crettol, S
    Déglon, JJ
    Besson, J
    Croquette-Krokkar, M
    Gothuey, I
    Hämmig, R
    Monnat, M
    Hüttemann, H
    Baumann, P
    Eap, CB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) : 593 - 604
  • [38] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
  • [39] Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes
    Lewis, David F. V.
    Lake, Brian G.
    Ito, Yuko
    Dickins, Maurice
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2006, 21 (04) : 385 - 389
  • [40] Developmental expression of human hepatic CYP2C9 and CYP2C19
    Koukouritaki, SB
    Manro, JR
    Marsh, SA
    Stevens, JC
    Rettie, AE
    McCarver, DG
    Hines, RN
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03): : 965 - 974